MSCL: Phase II data for forazapadin in DMD and FSHD expected soon, with early signs of clinical benefit
Forazapadin, a novel therapy targeting muscle stem cell regeneration, is advancing through two phase II trials in DMD, with key data expected by year-end. Early results show improved muscle strength and fat fraction, and a phase II FSHD trial is set to launch soon.Based on Satellos Bioscience Inc…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.